<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961801</url>
  </required_header>
  <id_info>
    <org_study_id>PSCI-18-128</org_study_id>
    <nct_id>NCT04961801</nct_id>
  </id_info>
  <brief_title>Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia</brief_title>
  <official_title>Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Mineishi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GVHD remains a major cause of morbidity and mortality following SCT. The current standard of&#xD;
      care for prophylaxis against GVHD includes tacrolimus and methotrexate.&#xD;
&#xD;
      This study proposes to utilize acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, for&#xD;
      GVHD prophylaxis following allogeneic SCT.&#xD;
&#xD;
      The hypothesis is that the addition of acalabrutinib to our institutional standard GVHD&#xD;
      prophylaxis (tacrolimus and methotrexate) is safe, feasible, and effective in reducing both&#xD;
      the incidence and severity of acute GVHD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2030</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>30 days</time_frame>
    <description>Dose-limiting toxicity of acalabrutinib in combination with tacrolimus and methotrexate in early SCT for Phase I part of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>30 days</time_frame>
    <description>Maximum tolerated dose (MTD) of acalabrutinib in combination with tacrolimus and methotrexate in early SCT for Phase I part of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute GVHD grade II-IV</measure>
    <time_frame>180 days</time_frame>
    <description>Incidence of acute GVHD grade II-IV by day 180 for Phase II part of the study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Acalabrutinib in combination with tacrolimus and methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: To determine the maximum tolerated dose (MTD) of Acalabrutinib in combination with tacrolimus and methotrexate for Phase II.&#xD;
Phase II: To determine if acalabrutinib in combination with tacrolimus and methotrexate is safe and effective in reducing acute GVHD rate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib, tacrolimus, methotrexate</intervention_name>
    <description>For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia</description>
    <arm_group_label>Acalabrutinib in combination with tacrolimus and methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willingness and ability to sign the study-specific informed consent form&#xD;
&#xD;
          2. Willingness to comply with all study procedures and attend all study visits.&#xD;
&#xD;
          3. Participant with (a) B-cell malignancies or (b) AML (CD117 positive) who are&#xD;
             undergoing allogeneic SCT at Penn State Cancer Institute from an 8/8 matched unrelated&#xD;
             donor. Donor selection and screening criteria are to comply with 21 CRF Part 1271.&#xD;
&#xD;
          4. Male or female participant, age ≥ 18 and ≤ 75 years.&#xD;
&#xD;
          5. Ability to swallow oral medication.&#xD;
&#xD;
          6. Women of childbearing potential (WOCP) as defined as not surgically sterile or not&#xD;
             postmenopausal must have a negative serum pregnancy test at screening and a negative&#xD;
             urine pregnancy test within 7 days of beginning the condition regimen.&#xD;
&#xD;
          7. Men and WOCP must agree to use 2 medically accepted method of contraception and must&#xD;
             agree to continue use this method while on the trial and through at least one week&#xD;
             after the last dose of study drug. Acceptable methods of contraception include&#xD;
             abstinence, barrier method with spermicide, intrauterine device (IUD) known to have a&#xD;
             failure rate of less than 1% per year, or steroidal contraceptive (oral, transdermal,&#xD;
             implanted, or injected) in conjunction with a barrier method. Periodic abstinence&#xD;
             (e.g., calendar, ovulation, symptothermal, post ovulation methods) withdrawal,&#xD;
             spermicides only, or lactational amenorrhea are not acceptable methods of&#xD;
             contraception. WOCP must use a medically accepted method of contraception and must&#xD;
             agree to continue use this method from the time of signing the informed consent&#xD;
             through at least one week after the last dose of study drug.&#xD;
&#xD;
          8. Karnofsky Performance Scale (KPS) equal to or greater than 70%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Renal dysfunction with eGFR &lt;30/mL/minute/1.73 m2 by Cockroft-Gault formula.&#xD;
&#xD;
          2. Participant requires warfarin or vitamin K antagonist within one week of acalabrutinib&#xD;
             administration.&#xD;
&#xD;
          3. Participant requires treatment with a strong cytochrome P450 3A inducer or inhibitor.&#xD;
&#xD;
          4. Treatment with post-transplant cyclophosphamide&#xD;
&#xD;
          5. Treatment with any other investigational products within 21 days of conditioning&#xD;
             regimen.&#xD;
&#xD;
          6. Known hypersensitivity to acalabrutinib, tacrolimus and methotrexate and their&#xD;
             excipients.&#xD;
&#xD;
          7. Active uncontrolled infections&#xD;
&#xD;
          8. Human immunodeficiency virus (HIV) positivity.&#xD;
&#xD;
          9. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody&#xD;
             (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need&#xD;
             to have a negative polymerase chain reaction (PCR) and must be willing to undergo DNA&#xD;
             PCR testing during the study to be eligible. Those who are HBsAg positive or hepatitis&#xD;
             B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will&#xD;
             need to have a negative PCR result to be eligible. Those who are hepatitis C PCR&#xD;
             positive will be excluded.&#xD;
&#xD;
         10. Any serious medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of study procedures.&#xD;
&#xD;
         11. Diagnosed or treated for another malignancy within 2 years before study registration&#xD;
             or previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Participant with non-melanoma skin cancer or carcinoma in situ of any type&#xD;
             are not excluded if they have undergone resection.&#xD;
&#xD;
         12. Participant with coagulopathy or bleeding disorder.&#xD;
&#xD;
         13. Known hepatic cirrhosis or severe pre-existing hepatic impairment (ALT and/or AST more&#xD;
             than 3x greater than upper limit of normal, Total Bilirubin more than 2x greater than&#xD;
             upper limit of normal)&#xD;
&#xD;
         14. Uncontrolled high blood pressure (i.e., systolic blood pressure &gt; 180 mm Hg, diastolic&#xD;
             blood pressure &gt; 95 mm Hg).&#xD;
&#xD;
         15. Uncontrolled or symptomatic cardiac arrhythmia&#xD;
&#xD;
         16. Left ventricular ejection fraction (LVEF) &lt; 40% as assessed by echocardiogram or&#xD;
             radionuclide angiography, or NYHA class 3 or 4 heart failure&#xD;
&#xD;
         17. Myocardial infarction within 6 months of signing consent.&#xD;
&#xD;
         18. History of stroke or intracranial hemorrhage within 6 months of signing consent.&#xD;
&#xD;
         19. Breastfeeding or pregnant.&#xD;
&#xD;
         20. Has difficulty with or is unable to swallow oral medication, or has significant&#xD;
             gastrointestinal disease that would limit absorption of oral medication.&#xD;
&#xD;
         21. Suspected or confirmed PML(Progressive Multifocal Leukoencephalopathy)&#xD;
&#xD;
         22. Requires treatment with proton-pump inhibitors. (Participants receiving proton-pump&#xD;
             inhibitors who switch to H2-receptor antagonists or antacids are eligible for&#xD;
             enrollment.)&#xD;
&#xD;
         23. FVC, FEV1, or DLCO (corrected with hemoglobin) less than 40% of expected value.&#xD;
&#xD;
         24. Prothrombin time (PT)/INR or aPTT (in the absence of lupus anticoagulant) &gt;2x ULN.&#xD;
&#xD;
         25. Major surgical procedure within 28 days of first dose of study drug. Note: If a&#xD;
             subject had major surgery, they must have recovered adequately from any toxicity&#xD;
             and/or complications from the intervention before the first dose of study drug.&#xD;
&#xD;
         26. Concurrent participation in another therapeutic clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kevin Rakszawski</last_name>
    <phone>7175318678</phone>
    <email>krakszawski@pennstatehealth.psu.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Shin Mineishi</investigator_full_name>
    <investigator_title>Professor, Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>Graft-Versus-Host Disease Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Acalabrutinib</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

